Six field experiments were established in southwestern Ontario in 2021 and 2022 to evaluate if the addition of a grass herbicide (acetochlor, dimethenamid-p, flufenacet, pendimethalin, pyroxasulfone, or S-metolachlor) to tolpyralate + atrazine improves late-season weed control in corn. Tolpyralate + atrazine caused 12% and 5% corn injury at 1 and 4 weeks after herbicide application (WAA); corn injury was not increased with the addition of a grass herbicide. Weed inference reduced corn yield 60%. The addition of a grass herbicide to tolpyralate + atrazine did not enhance velvetleaf control. The addition of acetochlor or dimethenamid-p to tolpyralate + atrazine enhanced pigweed species control 4% 4 WAA; the addition of other grass herbicides tested did not increase pigweed species control. The addition of acetochlor enhanced common ragweed control 5% at 4 WAA and the addition of acetochlor or dimethenamid-p enhanced common ragweed control 8% at 8 WAA; the addition of other grass herbicides did not improve common ragweed control. The addition of acetochlor to tolpyralate + atrazine enhanced common lambsquarters control up to 4%; there was no enhancement in common lambsquarters control with the addition of the other grass herbicides. Tolpyralate + atrazine controlled barnyardgrass 90% and 78% at 4 and 8 WAA, respectively; the addition of a grass herbicide enhanced barnyardgrass control 9 to 10% and 21% at 4 and 8 WAA, respectively. Tolpyralate + atrazine controlled green or giant foxtail 80% and 69% at 4 and 8 WAA, respectively; the addition of a grass herbicide enhanced foxtail species control 15 to 19% and 24 to 29% at 4 and 8 WAA, respectively. This research shows that adding a grass herbicide to tolpyralate + atrazine mixture can improve weed control efficacy, especially increased annual grass control in corn production.

A significant percentage of people with bipolar disorder (BD) exhibit suboptimal functional adjustment, even when appropriately treated and after symptomatic recovery is achieved. Given that cognitive impairment is one of the strongest correlates of socio-occupational outcomes and quality of life in BD, cognitive remediation (CR) is currently acknowledged as a promising treatment that could help bridge the gap between symptomatic and full functional recovery. The aim of this review was to explore the efficacy of CR approaches in improving cognitive and functional outcomes in BD patients. PubMed, PsycINFO, and CENTRAL were searched from inception to November 2022. Randomized controlled trials exploring the effects of CR on cognition and/or functional adjustment in adult BD patients were eligible. Ten studies based on seven independent trials (n = 586) were included. Change-score effect sizes (Hedges' g) were obtained for efficacy outcome measures and combined by means of meta-analytic procedures. Small but significant overall effects were observed for working memory (g = 0.32, 95% CI 0.11–0.52), planning (g = 0.30, 95% CI 0.03–0.56), and verbal learning (g = 0.40, 95% CI 0.15–0.66). However, CR was not found to exert any significant effects on functional outcomes at treatment completion or at follow-up assessment. Although CR may modestly enhance the cognitive performance of BD patients, this effect does not translate into an improvement at the functional level. The current data do not support the inclusion of CR as a treatment recommendation in clinical practice guidelines for the management of BD.

Interim analyses in clinical trials can take on a multitude of forms. They are often used to guide Data and Safety Monitoring Board (DSMB) recommendations to study teams regarding recruitment targets for large, later-phase clinical trials. As collaborative biostatisticians working and teaching in multiple fields of research and across a broad array of trial phases, we note the large heterogeneity and confusion surrounding interim analyses in clinical trials. Thus, in this paper, we aim to provide a general overview and guidance on interim analyses for a nonstatistical audience. We explain each of the following types of interim analyses: efficacy, futility, safety, and sample size re-estimation, and we provide the reader with reasoning, examples, and implications for each. We emphasize that while the types of interim analyses employed may differ depending on the nature of the study, we would always recommend prespecification of the interim analytic plan to the extent possible with risk mitigation and trial integrity remaining a priority. Finally, we posit that interim analyses should be used as tools to help the DSMB make informed decisions in the context of the overarching study. They should generally not be deemed binding, and they should not be reviewed in isolation.

The number of grassroots members of populist radical right (PRR) parties is on the rise, in contrast to the trend of membership decline in mainstream parties. While scholars have explained this by studying PRR parties' organizational strategies, I focus on party members and ask: Why do people join PRR parties? To answer this, I look not only at motivations, which is the dominant framework in party membership studies, but also at triggers – factors activating those motivations. Drawing on collective action scholarship, I argue that grievances and efficacy can work as triggers for joining PRR parties. Using interviews with 82 members of the Bharatiya Janata Party, the League in Italy and the Sweden Democrats, I uncover three elements in the path to PRR party membership: disaffection, affiliation and action. As well as questioning established narratives on why citizens join parties, my findings provide a novel theoretical framework to investigate this form of political participation.

Medical devices form a large heterogeneous group of products ranging from simple tools to medical testing and implants, the safety and efficacy of which are strictly regulated in all developed countries. Thanks to the health and cost benefits, medical devices have also found their way into veterinary medicine but, surprisingly, the regulation of these products is far less complex or, in some cases, missing altogether. Given the complexity and potential hazards of certain veterinary devices, the current state of affairs may lead to health and safety risks, both for animals and personnel involved. This review is the first to systematically map the current situation in the EU, revealing health and safety risks in practice for both animals and personnel involved and discussing them in a broader context. Only six out of the EU's 28 member states (Belgium, Croatia, Czech Republic, Germany, Hungary, and Slovakia) were found to have at least a degree of regulation of veterinary devices. As a result, a single product may be regulated as a veterinary medicinal product, a veterinary medical device or not be regulated at all, depending on the particular EU member state in question. As things stand, veterinary medicine makes use of all kinds of medical devices, including human products, regardless of their regulatory status and (pre-market) control. However, the use of such devices may influence the health and well-being of animals. Several measures are therefore suggested to attain the required levels of safety and efficacy surveillance for veterinary medical devices without creating excessive administration.

Little information is available on the relative efficacy of Group 4 herbicides for glyphosate-resistant (GR) horseweed management in soybean. Five field research experiments were conducted in growers’ fields from 2020 to 2021 to determine GR horseweed control with Group 4 herbicides applied preplant (PP) alone and in a mixture. There was minimal soybean injury (≤4%) with herbicides evaluated. Dicamba, 2,4-D, or halauxifen-methyl applied PP controlled GR horseweed 92% to 96%, 73% to 76%, and 85% to 89%, respectively. The mixtures of dicamba + 2,4-D, dicamba + halauxifen-methyl and dicamba + 2,4-D + halauxifen-methyl provided 97% to 99% control of GR horseweed, similar to dicamba applied alone. The mixture of 2,4-D + halauxifen-methyl provided 93% to 94% control of GR horseweed. Dicamba + saflufenacil controlled GR horseweed at 98%. Dicamba alone, dicamba + 2,4-D ester, dicamba + halauxifen-methyl, and dicamba + 2,4-D ester + halauxifen-methyl decreased GR horseweed density 97%, 99%, 99%, and 98%, respectively, similar to a 98% density reduction with dicamba + saflufenacil. Other herbicide treatments had no effect on GR horseweed density. Dicamba, 2,4-D, and halauxifen-methyl applied PP decreased GR horseweed dry biomass by 99%, 76%, and 72%, respectively. The mixtures of dicamba + 2,4-D, dicamba + halauxifen-methyl, and dicamba + 2,4-D + halauxifen-methyl decreased GR horseweed dry biomass by 99% to 100%, similar to a 99% dry biomass reduction with dicamba + saflufenacil. The mixture of 2,4-D + halauxifen-methyl decreased GR horseweed dry biomass by 94%. Soybean yield was decreased by 61% when GR horseweed was left uncontrolled. Results show that Group 4 herbicides that include dicamba applied PP can be very effective in managing GR horseweed in soybean.

It is estimated that electroconvulsive therapy is still administered to approximately a million people a year. It involves passing enough electric current through the human brain, eight to twelve times, to cause convulsions, in the hope of somehow alleviating emotional suffering, primarily depression. There have only ever been 11 placebo-controlled studies (where general anaesthesia is administered but the electric shock is withheld), all of which were pre-1986, had very small sample sizes and were seriously methodologically flawed. Five of these studies found no difference between the two groups at the end of treatment, four found ECT produced better outcomes for some patients, and two produced mixed results, including one where psychiatrists' ratings produced a difference, but the ratings of nurses and patients did not. In the 80 years since the first ECT no studies have found any evidence that ECT is better than placebo beyond the end of treatment. Nevertheless, all five meta-analyses relying on these studies have somehow concluded that ECT is more effective than placebo despite the studies' multiple failings. Meanwhile, evidence of persistent or permanent memory loss in 12% to 55% of patients has accumulated. Attempts to highlight this failure of ECT proponents to provide robust evidence that their treatment is effective and safe are routinely dismissed, diminished, denied and denounced. This paper responds to one such attempt, by Drs Meechan, Laws, Young, McLoughlin and Jauhar, to discredit two systematic reviews of the eleven pre-1986 studies, in 2010 and 2019, the latter of which also reviewed five meta-analyses that had ignored the studies' failings. The criticisms and claims of the recent crtiique of the two systematic reviews are examined in detail, by the first author of both reviews, for accuracy, relevance and logic. The critique is found to include multiple errors, misrepresentations, omissions, inconsistencies and logical flaws. It is concluded that Meechan et al. fail to make a fact-based, coherent argument against suspending ECT pending a series of large, carefully designed placebo-controlled studies to establish whether ECT does have any beneficial effects against which to weigh the significant established adverse effects.

The use of a Kaplan–Meier (K–M) survival time approach is generally considered appropriate to report antimalarial efficacy trials. However, when a treatment arm has 100% efficacy, confidence intervals may not be computed. Furthermore, methods that use probability rules to handle missing data for instance by multiple imputation, encounter perfect prediction problem when a treatment arm has full efficacy, in which case all imputed values are either treatment success or all imputed values are failures. The use of a survival K–M method addresses this imputation problem in estimating the efficacy estimates also referred to as cure rates. We discuss the statistical challenges and propose a potential way forward.

The proposed approach includes the use of K–M estimates as the main measure of efficacy. Confidence intervals could be computed using the binomial exact method. p-Values for comparison of difference in efficacy between treatments can be estimated using Fisher’s exact test. We emphasize that when efficacy rates are not 100% in both groups, the K–M approach remains the main strategy of analysis considering its statistical robustness in handling missing data and confidence intervals can be computed under such scenarios.

Due to the coronavirus disease 2019 (COVID-19) pandemic, there is currently a need for accurate, rapid, and easy-to-administer diagnostic tools to help communities manage local outbreaks and assess the spread of disease. The use of artificial intelligence within the domain of breath analysis techniques has shown to have potential in diagnosing a variety of diseases, such as cancer and lung disease, by analyzing volatile organic compounds (VOCs) in exhaled breath. This combined with their rapid, easy-to-use, and noninvasive nature makes them a good candidate for use in diagnosing COVID-19 in large scale public health operations. However, there remains issues with their implementation when it comes to the infrastructure currently available to support their use on a broad scale. This includes issues of standardization, and whether or not a characteristic VOC pattern can be identified for COVID-19. Despite these difficulties, breathalyzers offer potential to assist in pandemic responses and their use should be investigated.